Jason Luke

Jason Luke has emerged as a leading investigator in melanoma adjuvant immunotherapy with a particular focus on STING pathway activation and innate immune priming strategies. His research explores biomarkers predictive of adjuvant immunotherapy benefit in resected stage III melanoma and mechanisms of immune evasion in the melanoma microenvironment. He has led clinical trials of novel IO combinations in adjuvant settings and contributed to understanding why some patients with resected high-risk melanoma achieve durable remissions while others relapse. His work on STING agonists and intratumoral immunotherapy has opened new avenues for combining local immune activation with systemic checkpoint blockade.